Current medication treatments for anxiety disorders have long relied on Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), and benzodiazepines. The investigational medications now in development represent a shift toward new biological targets, precision delivery systems, and treatment approaches that go beyond traditional antidepressant mechanisms.